Aug 2025· BMJ digital health & AI· Vol 1, pp. e000114· 3 citations· 39 references
Medicine
TL;DR
An ML model is created to predict serious cardiac outcomes using a deployment-aware framework leveraging real-world data and the best-performing model in the retrospective phase was LightGBM trained on all inpatients.
Abstract
Objectives Objectives were to develop a machine learning (ML) model based on electronic health record data to predict the risk of a serious cardiac outcome within the next 3 months among patients admitted to the cardiology service using retrospective data, and to evaluate the model prospectively in a silent trial (predictions not provided to clinicians). Methods and analysis Admissions between 2 June 2018 to 21 August 2023 (retrospective) and 10 May 2024 to 26 October 2024 (prospective) to the cardiology service were included. Data were a curated and validated source named SickKids Enterprise-wide Data in Azure Repository. Prediction time was the morning following admission. The label was a composite outcome consisting of ventricular assist device procedure, heart transplant waitlisting or death within 3 months. We trained models using L2-regularised logistic regression, LightGBM and XGBoost. Training cohorts include the target cohort and all inpatient admissions. Results The best-performing model in the retrospective phase was LightGBM trained on all inpatients. There were 51 571 admissions used for model development in the retrospective phase and 515 admissions in the prospective silent trial. The number of features in the final model was 7553. The area under the receiver operating characteristic curve was 0.88 (95% CI 0.88 to 0.89) for retrospective and 0.82 (95% CI 0.79 to 0.83) for prospective silent trial phases. Based on a threshold selected during the retrospective phase, silent trial positive and negative predictive values were 0.19 and 0.97, respectively. Conclusions We created an ML model to predict serious cardiac outcomes using a deployment-aware framework leveraging real-world data. Postdeployment evaluation will be an important future goal.
XGBoost achieved strong discrimination for predicting pneumonia death and identified clinically coherent risk drivers through SHAP, which supports the potential utility of explainable machine learning for risk stratification and earlier escalation of care in HF populations.
Y. Qi, Q. Ren, A. Mastumoto et al.· European Heart Journal· 0 citations
Abstract Background Heart failure (HF) represents a major public health challenge in Portugal, associated with high mortality and healthcare costs. This study aimed to develop and validate artificial intelligence models to predict in-hospital mortality among HF patients at the Baixo Alentejo Local Health Unit, using in...
J. Diniz, S. Duarte, A. Dionísio et al.· European Journal of Public H...· 0 citations
Although the model shows potential for identifying high-risk individuals at the 24-hour prediction landmark, further prospective validation and clinical impact assessment are required before routine clinical implementation.
Zhang-Cong Lu, Ling-Han Hu, Peng-Fei Shui et al.· British journal of hospital...· 0 citations
A clinically applicable machine learning model demonstrating excellent predictive performance for SCD risk in Chinese children with HCM is developed and independently validated.
B. Han, Y. Meng· European Heart Journal· 0 citations
Background Early risk assessment is a routine part of neurocritical care, yet mortality prediction remains difficult because neurological injury often coexists with respiratory, circulatory, renal, and inflammatory dysfunction. This study aimed to develop and externally validate an interpretable machine learning (ML) m...
Xiao Cheng, Jian-Xin Ye, H. Wei· Frontiers in Neurology· 0 citations
Background Accurate risk stratification is essential in acute heart failure (AHF), which carries substantial in-hospital mortality. The Get With The Guidelines–Heart Failure (GWTG-HF) score is widely used, but its performance may vary across populations, and prospective data from Southeast Asia are scarce. We developed...
Sy Van Hoang, K. Nguyen, T. Nguyen et al.· Frontiers in Cardiovascular...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.